Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer

Frontiers in Immunology

Immunology

Yutao Li¹  Ingo G. H. Schmidt-Wolf¹  Amit Sharma²  Chunmei Hu³  Yi Zhao⁴  Min Liu⁴  Haotian Liu⁴ 

[1] Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany;Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany;Department of Neurosurgery, University Hospital Bonn, Bonn, Germany;Department of Otolaryngology-Head and Neck Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China;Department of Otolaryngology-Head and Neck Surgery, West China Hospital of Sichuan University, Chengdu, China;

关键词: CAR-T cell therapy;    head and neck cancer;    head and neck squamous cell carcinoma;    immunotherapy;    immune checkpoint inhibitors;   

DOI  :  10.3389/fimmu.2023.1213716

 received in 2023-04-28, accepted in 2023-06-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

Head and neck cancer (HNC) ranks as the sixth most prevalent type of cancer globally and accounts for about 4% of all types of cancer. Among all HNC, most are head and neck squamous cell carcinoma (HNSCC) with clinical therapies that include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and multimodal treatments. In recent years, chimeric antigen receptor (CAR)-T cell immunotherapy has significantly transformed the therapeutic approaches for leukemia and lymphoma and has garnered increased attention as a potential treatment for a wide range of cancers. However, CAR-T immunotherapy in solid tumors, especially HNSCCs, lags significantly behind due to the paucity of tumor-specific antigens, high levels of tumor heterogeneity, immunosuppressive tumor microenvironment, the risk of treatment-related toxicities and off-target adverse events in HNSCCs. The objective of this review is to explore the advancement of CAR-T cell therapy in the treatment of HNSCCs. We aim to outline the targeted antigens in HNSCCs, highlight the challenges and potential solutions, and discuss the relevant combination therapies. Our review presents a comprehensive overview of the recent developments in CAR-T cell therapy for HNSCCs, and provides valuable insights into future research avenues.

【 授权许可】

Unknown   
Copyright © 2023 Hu, Liu, Li, Zhao, Sharma, Liu and Schmidt-Wolf